BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

400 related articles for article (PubMed ID: 18391633)

  • 1. Recent developments in urologic oncology: positron emission tomography molecular imaging.
    Bouchelouche K; Oehr P
    Curr Opin Oncol; 2008 May; 20(3):321-6. PubMed ID: 18391633
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Positron emission tomography and positron emission tomography/computerized tomography of urological malignancies: an update review.
    Bouchelouche K; Oehr P
    J Urol; 2008 Jan; 179(1):34-45. PubMed ID: 17997425
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Positron emission tomography for prostate, bladder, and renal cancer.
    Schöder H; Larson SM
    Semin Nucl Med; 2004 Oct; 34(4):274-92. PubMed ID: 15493005
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PET in the management of urologic malignancies.
    Kumar R; Zhuang H; Alavi A
    Radiol Clin North Am; 2004 Nov; 42(6):1141-53, ix. PubMed ID: 15488563
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Positron-emission tomography imaging in urological oncology: Current aspects and developments.
    Rauscher I; Eiber M; Weber WA; Gschwend JE; Horn T; Maurer T
    Int J Urol; 2018 Nov; 25(11):912-921. PubMed ID: 30103285
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Positron emission tomography in uro-oncology.
    Hain SF
    Cancer Imaging; 2005 Jan; 5(1):1-7. PubMed ID: 16154810
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PET/Computed Tomography in Renal, Bladder, and Testicular Cancer.
    Bouchelouche K; Choyke PL
    PET Clin; 2015 Jul; 10(3):361-74. PubMed ID: 26099672
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Positron emission tomography in urologic oncology.
    Shvarts O; Han KR; Seltzer M; Pantuck AJ; Belldegrun AS
    Cancer Control; 2002; 9(4):335-42. PubMed ID: 12228759
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Possible role of FDG-PET in the evaluation of urologic malignancies.
    Bender H; Schomburg A; Albers P; Ruhlmann J; Biersack HJ
    Anticancer Res; 1997; 17(3B):1655-60. PubMed ID: 9179213
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FDG in Urologic Malignancies.
    Høilund-Carlsen PF; Poulsen MH; Petersen H; Hess S; Lund L
    PET Clin; 2014 Oct; 9(4):457-68, vi. PubMed ID: 26050947
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of 11C-choline with 18F-FDG in positron emission tomography/computerized tomography for staging urothelial carcinoma: a prospective study.
    Golan S; Sopov V; Baniel J; Groshar D
    J Urol; 2011 Aug; 186(2):436-41. PubMed ID: 21679983
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Recommendation for clinical practice: use of PET-FDG in cancer of the kidney, prostate, testicles, and the urinary bladder].
    Bourguet P; Planchamp F; Montravers F; Vincendeau S; Courbon F; Edeline V; Helal BO; Rossi D; Villers A; ; ; ; ; ; ; ;
    Bull Cancer; 2006 Dec; 93(12):1228-32. PubMed ID: 17191352
    [No Abstract]   [Full Text] [Related]  

  • 13. Nuclear medicine studies of the prostate, testes, and bladder.
    Jana S; Blaufox MD
    Semin Nucl Med; 2006 Jan; 36(1):51-72. PubMed ID: 16356796
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PET imaging in urology: a rapidly growing successful collaboration.
    Farolfi A; Koschel S; Murphy DG; Fanti S
    Curr Opin Urol; 2020 Sep; 30(5):623-627. PubMed ID: 32701721
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 18F-FDG PET/CT delayed images after diuretic for restaging invasive bladder cancer.
    Anjos DA; Etchebehere EC; Ramos CD; Santos AO; Albertotti C; Camargo EE
    J Nucl Med; 2007 May; 48(5):764-70. PubMed ID: 17475965
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Update on positron emission tomography for imaging of prostate cancer.
    Kitajima K; Murphy RC; Nathan MA; Sugimura K
    Int J Urol; 2014 Jan; 21(1):12-23. PubMed ID: 23991644
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Standards, Options and Recommendations for the use of PET-FDG in cancerology. Results in urological cancers].
    Bourguet P;
    Bull Cancer; 2003 Feb; 90 Spec No():S80-7. PubMed ID: 12739339
    [No Abstract]   [Full Text] [Related]  

  • 18. Value of [11C]choline-positron emission tomography for re-staging prostate cancer: a comparison with [18F]fluorodeoxyglucose-positron emission tomography.
    Picchio M; Messa C; Landoni C; Gianolli L; Sironi S; Brioschi M; Matarrese M; Matei DV; De Cobelli F; Del Maschio A; Rocco F; Rigatti P; Fazio F
    J Urol; 2003 Apr; 169(4):1337-40. PubMed ID: 12629355
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [2006 technology monitoring report: clinical practice guideline: use of FDG-PET in kidney, prostate, testis and bladder cancers].
    Bourguet P; Planchamp F; Montravers F; Vincendeau S; ;
    Prog Urol; 2007 Apr; 17(2):172-5. PubMed ID: 17489312
    [No Abstract]   [Full Text] [Related]  

  • 20. PET-imaging in tumors of the reproductive trac.
    Reinhardt MJ; Matthies A; Biersack HJ
    Q J Nucl Med; 2002 Jun; 46(2):105-12. PubMed ID: 12114873
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.